Aptevo Therapeutics Inc. (APVO) and PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) Comparison side by side

We are contrasting Aptevo Therapeutics Inc. (NASDAQ:APVO) and PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) on their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptevo Therapeutics Inc. 19.54M 2.03 49.36M -2.21 0.00
PhaseBio Pharmaceuticals Inc. N/A 173.17 21.51M -1.02 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Aptevo Therapeutics Inc. and PhaseBio Pharmaceuticals Inc.

Profitability

Table 2 represents Aptevo Therapeutics Inc. (NASDAQ:APVO) and PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Aptevo Therapeutics Inc. -252.61% -78.8% -51.1%
PhaseBio Pharmaceuticals Inc. 0.00% 0% 0%

Liquidity

Aptevo Therapeutics Inc.’s Current Ratio and Quick Ratio are 3.9 and 3.7 respectively. The Current Ratio and Quick Ratio of its competitor PhaseBio Pharmaceuticals Inc. are 3.2 and 3.2 respectively. Aptevo Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to PhaseBio Pharmaceuticals Inc.

Institutional & Insider Ownership

Institutional investors owned 32.9% of Aptevo Therapeutics Inc. shares and 52.36% of PhaseBio Pharmaceuticals Inc. shares. Aptevo Therapeutics Inc.’s share owned by insiders are 0.6%. Comparatively, 0.1% are PhaseBio Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aptevo Therapeutics Inc. -10.87% -40.92% -60.5% -59.88% -45.62% -51.65%
PhaseBio Pharmaceuticals Inc. 28.77% -28.18% 0% 0% 0% -26.6%

For the past year Aptevo Therapeutics Inc. was more bearish than PhaseBio Pharmaceuticals Inc.

Summary

PhaseBio Pharmaceuticals Inc. beats on 7 of the 9 factors Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.